5 results about "Phage antibodies" patented technology

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS135 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS135. The human neutralizing antibody specifically aiming at the F protein of the respiratory syncytial virus is successfully obtained by applying a phage antibody library technology; the obtained human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody variable region gene, Fab antibody gene and full antibody gene under the characteristics of each antibody gene are utilized to obtain the human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody. The antibody can be expressed and produced in prokaryotic cells, yeast cells, eukaryotic cells and any recombination system or any other reconstructed gene containing the antibody gene on the basis of the antibody, and an antibody product capable of neutralizing respiratory syncytial virus infection is obtained. And a specific antibody drug for clinically preventing and treating respiratory syncytial virus infection is prepared.

The application provides a Mycobacterium tuberculosis EspB monoclonal antibody, a preparation method and application thereof, and relates to the technical field of antibodies. The Mycobacterium tuberculosis EspB monoclonal antibody is obtained by immunizing animals with Mycobacterium tuberculosis cell walls and screening the monoclonal antibody through a phage antibody library technology. The application discloses the Mycobacterium tuberculosis EspB monoclonal antibody or a functional fragment thereof, and application thereof as an antibody conjugate and a composition. The monoclonal antibody has a specific nucleic acid sequence, and codes the specific EspB monoclonal antibody or the functional fragment thereof. The EspB monoclonal antibody obtained by the application has the characteristics of high sensitivity, high specificity and high affinity.

This invention discloses a shark-derived nanobody targeting the SARS-CoV-2 RBD protein and its applications. The nanobody's nucleotide sequence is shown in SEQ ID NO: 1, and its amino acid sequence is shown in SEQ ID NO: 5. Preparation involves immunizing a striped bamboo shark with the RBD protein, extracting total RNA from peripheral blood lymphocytes and reverse transcribing it into cDNA. The amplified VNAR fragment is then seamlessly ligated with amplified pR2 phage particles, transformed into TG1 competent cells, and a phage antibody library is constructed. SARS-CoV-2 RBD protein-specific nanobody sequences are screened from the library and recombinantly expressed to obtain the targeted shark-derived nanobody. The nanobody of this invention has a small molecular weight, allowing for the detection of the SARS-CoV-2 RBD antigen using paired nanobodies. It can be applied to immunoblotting, enzyme-linked immunosorbent assays (ELISA), and COVID-19 pharmaceutical applications related to the SARS-CoV-2 RBD protein.

The utility model relates to the technical field of bacteriophage culture and separation, in particular to a bacteriophage antibody separation and purification device, which is characterized in that when the bacteriophage antibody separation and purification device is used, bacteriophage and mixed liquid are poured into a stirring tank, and a stirring component is started, so that the stirring component stirs the bacteriophage and the mixed liquid in the horizontal direction and in the vertical direction simultaneously; when the inner side wall of the stirring tank needs to be cleaned, the washing assembly is operated to wash the inner side wall of the stirring tank, after stirring is completed, mixed liquid is discharged through the liquid discharging assembly, and convenience is improved; comprising a stirring tank and supporting legs, the multiple sets of supporting legs are installed at the bottom end of the stirring tank, the stirring device further comprises a liquid discharging assembly, a stirring assembly and a flushing assembly, the stirring assembly is arranged in the stirring tank, the flushing assembly is installed on the stirring tank, and the liquid discharging assembly is installed on the stirring tank.

The application discloses a shark-derived single-domain antibody binding SARS-CoV-2 RBD, the amino acid sequence of the single-domain antibody is shown as SEQ ID NO: 2 or SEQ ID NO: 4; nucleotides encoding the above-mentioned shark-derived single-domain antibody, characterized in that the nucleotide sequence is shown as SEQ ID NO: 1 or SEQ ID NO: 3; the application also provides a preparation method of the shark-derived single-domain antibody binding SARS-CoV-2 RBD, and the shark-derived single-domain antibody is obtained by sequentially performing immunization, constructing a phage antibody library, screening positive clones from the phage antibody library, finally adding an inducer for expression after large-scale culture, and collecting and purifying antibody proteins; the shark-derived single-domain antibody prepared by the application has good application prospects in the development of a new coronavirus disinfecting spray and a new coronavirus antigen detection kit.